MAIA Pharmaceuticals

What MAIA Pharmaceuticals does

MAIA Pharmaceuticals is a privately held specialty pharmaceutical company founded in 2013 and headquartered in Princeton, New Jersey. The company identifies, develops, manufactures, and markets innovative and niche generic pharmaceutical products for the U.S. market, operating with a small team of 1-10 employees. MAIA's commercial portfolio centers on two distinct assets: Sincalide for Injection (5 mcg), a cholecystokinin (CCK) analog marketed as the only FDA-approved sincalide product with a 24-month shelf life and distributed nationwide to U.S. healthcare professionals for diagnostic imaging procedures; and Teribone™ (teriparatide), a bone-forming osteoporosis therapy originally approved in Japan in 2011 that MAIA is developing and commercializing in the United States through a strategic collaboration with Asahi Kasei Pharma announced in February 2026.

The company's business model is anchored in pharmaceutical product sales generated through enterprise field sales targeting U.S. healthcare providers, supported by direct distribution to all 50 states and product-specific digital infrastructure (e.g., sincalide.com) that provides prescribing information, reimbursement resources, and direct ordering capabilities. Revenue mechanics appear to derive from one-time licensing arrangements with partners (e.g., Asahi Kasei Pharma) combined with prescription pharmaceutical sales to healthcare professionals and institutions. Customer segments are organized vertically around specific therapeutic use cases: diagnostic imaging specialists served by Sincalide and the broader osteoporosis patient population of over 10 million diagnosed U.S. individuals targeted by Teribone™.

MAIA's competitive position rests on regulatory exclusivity (sole FDA-approved sincalide), differentiated formulation attributes (preservative-free, polysorbate-free, 24-month shelf life, AP-rated), and partnership-driven access to de-risked therapeutic assets. Capital base is thin, with only $845,000 in disclosed funding raised in a single 2014 round, suggesting that scaling beyond a niche commercial footprint will require additional capital, partnership economics, or both. Leadership comprises Srikanth Sundaram as President and Chief Scientific Officer.

Name

MAIA Pharmaceuticals

Legal name

Maia Pharmaceuticals, Inc.

Website

https://maiapharma.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Short description

MAIA Pharmaceuticals is a Princeton-based specialty pharmaceutical company that develops, manufactures, and markets niche generic and innovative pharmaceutical products for U.S. healthcare professionals, including Sincalide for Injection and the Teribone™ osteoporosis therapy commercialized via Asahi Kasei Pharma.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Generic pharmaceuticals
• Specialty pharma products
• Injectable diagnostics
• Osteoporosis therapeutics
• Prescription drug development

Headquarters

HQ city

Princeton

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

1. Pharmaceutical Product Sales: MAIA Pharmaceuticals generates revenue through commercialization of established pharmaceutical therapies in the US market. The company obtains rights to develop and sell products (like Teribone™) through strategic partnerships, generating revenue from prescription pharmaceutical sales to healthcare providers and patients.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

MAIA Pharmaceuticals identifies, develops, manufactures and markets innovative and niche generic pharmaceutical products in the United States. The company's current commercial portfolio includes Sincalide for Injection (5 mcg), an FDA-approved cholecystokinin analog used in diagnostic imaging procedures, and Teribone™ (teriparatide), a bone-forming osteoporosis therapy being developed for U.S. commercialization through a strategic collaboration with Asahi Kasei Pharma.

Product overview

MAIA Pharmaceuticals operates as a pharmaceutical company with two distinct products in its portfolio. The company's primary product is Sincalide for Injection (5 mcg), an FDA-approved cholecystokinin (CCK) analog for diagnostic imaging applications, which is the only FDA-approved Sincalide with 24-month shelf life. Additionally, MAIA has entered a strategic collaboration with Asahi Kasei Pharma to develop and commercialize Teribone™ (teriparatide), an established bone-forming osteoporosis therapy for the U.S. market, which MAIA will lead in development and commercialization.

Differentiator

Problem solved

Functional benefit

Brands

• Teribone™: A bone-forming osteoporosis therapy (teriparatide) with once- or twice-weekly dosing profile, originally approved in Japan in 2011.
• Sincalide for Injection

Products and services

• Sincalide for Injection, 5 mcg A cholecystokinin (CCK) analog for injection indicated in adults to stimulate gallbladder contraction for diagnostic imaging, to obtain concentrated bile samples via duodenal aspiration, to stimulate pancreatic secretion in combination with secretin, and to accelerate transit of a barium meal through the small bowel. It is the only FDA-approved Sincalide product with a 24-month shelf life and is offered to U.S. healthcare professionals.
• Teribone™ (teriparatide) A bone-forming (anabolic) osteoporosis therapy based on teriparatide, originally approved in Japan in 2011. It features a once- or twice-weekly dosing regimen designed to improve patient adherence compared with daily alternatives. Being developed for U.S. commercialization through MAIA's collaboration with Asahi Kasei Pharma.

Quantifiable outcome

• Over 10 million diagnosed osteoporosis patients in the addressable US market

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Asahi Kasei PharmacoreStrategic or Co-development Partner · 19 February 2026MAIA Pharmaceuticals entered a strategic collaboration with Asahi Kasei Pharma to develop and commercialize Teribone™ (teriparatide) in the United States for treating osteoporosis. Under the agreement, MAIA leads U.S. development and commercialization of the established bone-forming therapy, which was originally approved in Japan in 2011. The partnership aligns Asahi Kasei Pharma's goal of extending global reach of proprietary therapies with MAIA's goal of commercializing established therapies in the significant US osteoporosis market of over 10 million diagnosed patients.

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Endo International: Large specialty pharmaceutical company with a portfolio of branded and generic injectable, urology, and specialty care products. Operates broadly in the same niche specialty pharma space where MAIA competes.
• Amneal Pharmaceuticals: Integrated specialty and generics pharmaceutical company with broad portfolio across injectables, oral solids, and specialty care. Comparable to MAIA in the niche/specialty generic product development and commercialization space.
• Hikma Pharmaceuticals: Multinational specialty and generic injectable pharmaceutical company with significant US presence. Comparable to MAIA in the niche injectable and specialty hospital products category.

Direct peers

• Lannett Company: Generic and specialty pharmaceutical company focused on niche products with limited competition. Comparable business model to MAIA's focus on identifying, developing, and marketing differentiated niche generic products.
• Slayback Pharma: Specialty generic pharmaceutical company focused on niche, complex generics and specialty products. Closely comparable to MAIA's niche generic product identification and commercialization model.
• ANI Pharmaceuticals: Specialty generics company that acquires, develops, and markets niche branded and generic pharmaceuticals, including injectables and women's health products. Closely parallels MAIA's strategy of identifying and commercializing niche specialty products.
• Radius Health: Specialty pharmaceutical company focused on osteoporosis and endocrine diseases. Directly comparable to MAIA's Teribone™ (teriparatide) bone-forming therapy focus in the US osteoporosis market.
• Eagle Pharmaceuticals: Specialty pharmaceutical company focused on developing and commercializing niche injectable and hospital-based products, mirroring MAIA's model of bringing differentiated specialty injectables (like Sincalide) to the US market.
• Harrow Health: Specialty pharmaceutical company that develops, acquires, and commercializes niche branded ophthalmic and specialty products. Similar small-cap specialty pharma profile to MAIA.

Regional players

• Fosun Pharma: Chinese-based multinational pharmaceutical company with US specialty operations. Linked to MAIA's Sincalide product and operates in comparable injectable/specialty pharmaceutical categories globally.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/maia-pharmaceuticals-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MAIA Pharmaceuticals